Figure 1.
Distribution of the collected blood samples following LMWH presence and last administration. The 79 blood samples included in the analyses were collected from patients receiving rivaroxaban at trough concentrations (CTROUGH) or before an invasive procedure. For these samples, an estimation of rivaroxaban plasma concentrations with 3 chromogenic assays (Biophen DiXaI, Biophen DiXaI LOW, and STA LAX) was performed and compared to measurements obtained by LC-MS/MS. Stratifications were performed according to heparin bridging. LMWH indicates low-molecular-weight heparin; LC-MS/MS, liquid chromatography coupled with mass spectrometry.